Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PEDS2: 12-month lasmiditan study in children and adolescents with migraine
NL-OMON60203Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lasmiditan in migraine, sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Treatment Emergent Adverse Events by treated migraine attack and Percentage of participants with discontinuations due to adverse events. Started Apr 2021; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON60203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60203.